Literature DB >> 23970453

Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis.

M E Chua1, K G Escusa, S Luna, L C Tapia, B Dofitas, M Morales.   

Abstract

The aim of this study was to synthesize and present the latest available evidence regarding the use of oestrogen antagonists as empiric medical therapy for idiopathic male infertility with oligo and/or asthenoteratozoospermia through meta-analysis of randomized controlled trials (RCTs). Systematic literature acquisition was done for English and other foreign language biomedical databases up to March, 2013. RCTs relevant to the topic were identified and critically appraised independently by two physician reviewers. Dichotomous data of pregnancy rate and adverse events were extracted for calculation of odds ratio (OR) and 95% confidence interval (CI). Effect estimates were pooled using Peto method with fixed effect model. The continuous data of semen and endocrine parameters were calculated for the mean difference between pre- and post-treatment effects, the weighted mean difference (WMD) and SD between the control and intervention group were determined and pooled using the random effects model. Inter-study heterogeneity and publication bias were assessed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline for meta-analysis reporting was followed. Eleven RCTs of good methodological quality were included for meta-analysis. The pooled effect estimates showed that oestrogen antagonists use was associated with a statistically significant increased pregnancy rate compared with controls (pooled OR 2.42; 95% CI 1.47-3.94; p = 0.0004). Significant increase in sperm concentration (WMD 5.24; 95% CI 2.12, 88.37; p = 0.001) and per cent sperm motility (WMD 4.55; 95% CI 0.73, 8.37; p = 0.03) were also noted. While significant elevation of serum follicle stimulating hormone (WMD 4.19 95% CI 2.05, 6.34; p = 0.0001) and testosterone (WMD 54.59; 95% CI 15.92, 93.27; p = 0.006) was associated with its use. No significant difference in adverse event was noted between oestrogen antagonists-treated group and controls. The evidence suggests that oestrogen antagonists as empiric medical therapy for idiopathic male infertility with low non-serious adverse event associated, may increase spontaneous pregnancy rate, improve sperm concentration and per cent sperm motility.
© 2013 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  clomiphene citrate; empiric medical therapy; idiopathic male infertility; meta-analysis; oestrogen antagonists; pregnancy rate; tamoxifen citrate

Mesh:

Substances:

Year:  2013        PMID: 23970453     DOI: 10.1111/j.2047-2927.2013.00107.x

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  39 in total

Review 1.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

Review 2.  Hormone-Based Treatments in Subfertile Males.

Authors:  Darshan P Patel; Jason C Chandrapal; James M Hotaling
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

3.  Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia.

Authors:  Kai-fa Tang; Yi-li Zhao; Shang-shu Ding; Qi-fei Wu; Xing-yang Wang; Jia-qi Shi; Fa Sun; Jun-ping Xing
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

Review 4.  Hormonal therapy for non-obstructive azoospermia: basic and clinical perspectives.

Authors:  Koji Shiraishi
Journal:  Reprod Med Biol       Date:  2014-09-18

5.  Management of male factor infertility: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS) : Endorsing Organization: Italian Society of Embryology, Reproduction, and Research (SIERR).

Authors:  A Ferlin; A E Calogero; C Krausz; F Lombardo; D Paoli; R Rago; C Scarica; M Simoni; C Foresta; V Rochira; E Sbardella; S Francavilla; G Corona
Journal:  J Endocrinol Invest       Date:  2022-01-24       Impact factor: 4.256

Review 6.  Alternative treatment modalities for the hypogonadal patient.

Authors:  Landon W Trost; Mohit Khera
Journal:  Curr Urol Rep       Date:  2014-07       Impact factor: 3.092

7.  Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia.

Authors:  Li Guo; Jun Jing; Yu-Ming Feng; Bing Yao
Journal:  Int Urol Nephrol       Date:  2015-07-28       Impact factor: 2.370

8.  NORMALIZATION OF SERUM VITAMIN D IMPROVES SEMEN MOTILITY PARAMETERS IN PATIENTS WITH IDIOPATHIC MALE INFERTILITY.

Authors:  A Alzoubi; H Mahdi; S Al Bashir; O Halalsheh; M Al Ebbini; M Alzarir; K Al-Ahmar; M Alfaqih; A H Al-Hadidi
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

9.  Nonsurgical Management of Oligozoospermia.

Authors:  Jeremy T Choy; John K Amory
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

Review 10.  Male infertility due to testicular disorders.

Authors:  Aditi Sharma; Suks Minhas; Waljit S Dhillo; Channa N Jayasena
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.